| Literature DB >> 24507763 |
Shuxian Li, Xuejing Li, Yingshuo Wang, Jun Yang1, Zhimin Chen, Shigang Shan.
Abstract
BACKGROUND: Mycoplasma pneumoniae (M. pneumoniae) is one of the major etiological agents for community-acquired pneumonia (CAP) in all age groups. The early host response to M. pneumoniae infection relies on the concerted release of proteins with various biological activities. However, no comprehensive analysis of the secretory proteins has been conducted to date regarding the host response upon M. pneumoniae infection.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24507763 PMCID: PMC3922035 DOI: 10.1186/1471-2180-14-27
Source DB: PubMed Journal: BMC Microbiol ISSN: 1471-2180 Impact factor: 3.605
Figure 1Workflow chart of the experimental design.
Figure 2Verification of up- or down-regulated proteins during infection. (A) RT-PCR analysis and quantitative analysis data of 16 secertory proteins during M. pneumoniae infection. compared to control (p < 0.05); data are presented as means ± SD. (B) Western blot analysis for 6 secretory proteins from total cell lysates and culture supernatants. Representative images were from three independent experiments performed in duplicate. β-actin was used as internal control for total cell lysates.
Figure 3Cellular localization of identified proteins. (A) Distribution of the identified proteins based on gene ontology (GO) annotations. (B) Enrichment score of GO cellular component categories. DAVID 6.7 was used to analyze the GO classification of the identified proteins. Function annotation clustering was used to classify similar annotation terms together, and the enrichment score for each group was used to rank the overall over-representation of annotation terms. The higher the enrichment score, the more important were the members of the annotation cluster.
Figure 4Functional gene ontology (GO) analysis of cellular compartment distribution of the clusters of proteins that were up-regulated by treatment. Over-representation of GO categories was analyzed using the Biological Networks Gene Ontology plugin (BINGO, version 2.44). Over-representation statistics were calculated by using the hypergeometric analysis and Benjamini & Hochberg False Discovery Rate (FDR) correction. Only categories that are significantly enriched after correction are represented. The color scales indicate the p value range for over-representation. The node size is proportional to the number of proteins annotated with the GO term.
KEGG analysis of differential expressed protein after infection
| KEGG_PATHWAY | hsa00620:Pyruvate metabolism | 6 | 5.31 | 1.46E-04 | 3939, 4191, 4190, 231, 5315, 3945 |
| KEGG_PATHWAY | hsa00010:Glycolysis/Gluconeogenesis | 6 | 5.31 | 9.95E-04 | 3939, 7167, 2023, 5315, 3945, 2821 |
| KEGG_PATHWAY | hsa04114:Oocyte meiosis | 7 | 6.19 | 2.83E-03 | 10971, 7529, 5501, 801, 7534, 7532, 7531 |
| KEGG_PATHWAY | hsa00030:Pentose phosphate pathway | 4 | 3.54 | 3.92E-03 | 2539, 7086, 2821, 5226 |
| KEGG_PATHWAY | hsa00270:Cysteine and methionine metabolism | 4 | 3.54 | 9.38E-03 | 3939, 191, 3945, 2805 |
| KEGG_PATHWAY | hsa04722:Neurotrophin signaling pathway | 6 | 5.31 | 2.17E-02 | 10971, 7529, 801, 7534, 7532, 7531 |
| KEGG_PATHWAY | hsa00480:Glutathione metabolism | 4 | 3.54 | 2.65E-02 | 2950, 2539, 2936, 5226 |
| KEGG_PATHWAY | hsa05130:Pathogenic Escherichia coli infection | 4 | 3.54 | 3.72E-02 | 10971, 7534, 3875, 10376 |
| KEGG_PATHWAY | hsa04810:Regulation of actin cytoskeleton | 7 | 6.19 | 5.89E-02 | 80310, 4478, 5501, 2335, 81, 5216, 1072 |
| KEGG_PATHWAY | hsa00051:Fructose and mannose metabolism | 3 | 2.65 | 7.14E-02 | 7167, 231, 57016 |
| KEGG_PATHWAY | hsa04110:Cell cycle | 5 | 4.42 | 7.82E-02 | 10971, 7529, 7534, 7532, 7531 |
Immune response and stress related proteins that were up-regulated by infection
| 9611 | Response to wounding | B4GALT1|YWHAZ|PROCR|LGALS1|CLU|SERPINE1|NP|IGFBP4|FN1|MIF |
| 6950 | Response to stress | B4GALT1|YWHAZ|LGALS1|CLU|CST3|PRDX1|NP|TPM4|MIF|PFN1|LGALS3BP|PROCR|AKR1B1|SERPINE1|HSPB1|CTSD|IGFBP4|FN1|ADAM9 |
| 50896 | Response to stimulus | LDHA|YWHAZ|CLU|PRDX1|NP|TPM4|B2M|MIF|PFN1|APP|LGALS3BP|GOT1|PROCR|TGFBI|SERPINE1|ADAM9|ENO1|FN1|B4GALT1|LGALS1|CST3|GPI|NPC2|AKR1B1|CFL1|CTSD|HSPB1|IGFBP4|CALM1 |
| 9615 | Response to virus | NPC2|CLU|CFL1|HSPB1|ENO1 |
| 55114 | Oxidation reduction | ALDH1A1|LDHB|LDHA|AKR1B10|AKR1B1|TXN|PGD|PRDX4|TXNRD1|PRDX1 |
| 51707 | Response to other organism | NPC2|CLU|CFL1|SERPINE1|HSPB1|ENO1|B2M |
| 6979 | Response to oxidative stress | CLU|SERPINE1|PRDX1|TPM4|ADAM9 |
| 42221 | Response to chemical stimulus | YWHAZ|LGALS1|CLU|PRDX1|NP|TPM4|B2M|MIF|PFN1|GOT1|SERPINE1|CFL1|HSPB1|CALM1|ADAM9 |
| 9607 | Response to biotic stimulus | NPC2|CLU|CFL1|SERPINE1|HSPB1|ENO1|B2M |
| 10035 | Response to inorganic substance | SERPINE1|PRDX1|CALM1|ADAM9|B2M |
| 10033 | Response to organic substance | PFN1|GOT1|LGALS1|CLU|CFL1|SERPINE1|HSPB1|MIF|ADAM9|B2M |
| 42493 | Response to drug | YWHAZ|LGALS1|NP|MIF|B2M |
| 302 | Response to reactive oxygen species | SERPINE1|PRDX1|ADAM9 |
| 6952 | Defense response | B4GALT1|PFN1|LGALS3BP|YWHAZ|CLU|SERPINE1|CST3|PRDX1|IGFBP4|FN1|MIF |
| 6954 | Inflammatory response | B4GALT1|YWHAZ|CLU|IGFBP4|FN1|MIF |
| 50900 | Leukocyte migration | B4GALT1|MSN|MIF |
| 2376 | Immune system process | B4GALT1|GPI|YWHAZ|PROCR|CLU|MSN|NP|PRDX1|MIF|ADAM9|B2M |
| 2441 | Histamine secretion involved in inflammatory response | YWHAZ |
| 2477 | Antigen processing and presentation of exogenous peptide antigen via MHC class Ib | B2M |
| 2481 | Antigen processing and presentation of exogenous protein antigen via MHC class Ib, TAP-dependent | B2M |
| 2349 | Histamine production involved in inflammatory response | YWHAZ |
| 35491 | Positive regulation of leukotriene production involved in inflammatory response | SERPINE1 |
| 35490 | Regulation of leukotriene production involved in inflammatory response | SERPINE1 |
| 34241 | Positive regulation of macrophage fusion | ADAM9 |
| 6955 | Immune response | GPI|YWHAZ|PROCR|CLU|NP|PRDX1|MIF|B2M |
| 2443 | Leukocyte mediated immunity | YWHAZ|CLU|PRDX1 |
| 2684 | Positive regulation of immune system process | CLU|SERPINE1|NP|MIF|B2M |
Figure 5Protein interaction network analysis of the up-regulated proteins in -treated A549 cells. Using protein interaction network analysis tool (STRING database), three networks of the associated proteins were found among the up-regulated proteins. These included the network for stress response proteins (red circle), signaling pathway associated proteins (blue circle), and cellular metabolic proteins (green circle). Different line colors represent the types of evidence for the association.
Figure 6Protein interaction network generated with STRING software for down-regulated proteins in -treated A549 cells. Two major networks, e.g., glucose catabolic proteins (black circle) and biological process negative regulation associated proteins (purple circle) were found. Different line colors represent the types of evidence for the association.
Clinical information of patients with MPP or FB
| Age (years) | 4.88 ± 3.58 | 5.78 ± 2.46 | 0.326 |
| Gender (male/female) | 9/6 | 16/14 | 0.671 |
| Peripheral leukocyte (×109 cells/L) | 7.00 ± 1.64 | 9.06 ± 4.10 | 0.102 |
| Peripheral neutrophil (%) | 46.95 ± 20.89 | 63.90 ± 16.20 | 0.004 |
| BAL macrophage (%) | 84.73 ± 6.45 | 66.53 ± 13.71 | < 0.001 |
| BAL lymphocyte (%) | 9.73 ± 3.88 | 11.93 ± 6.39 | 0.229 |
| BAL neutrophil (%) | 5.53 ± 3.68 | 20.73 ± 13.47 | < 0.001 |
| BAL eosinophil (%) | 0.20 ± 0.41 | 0.83 ± 2.35 | 0.309 |
Data were expressed as mean ± SD. These variables were compared using Student’s t-test or Mann–Whitney U test.
Figure 7infection induces IL-33 expression. (A) A549 cells were treated with M. pneumoniae for 12 and 24 h, and IL-33 levels in the supernatants were measured by ELISA. Data are presented as means ± SD from at least three independent experiments. **, p < 0.01, compared with untreated A549 cells. (B) Concentration of IL-33 in patient plasma samples. (C) Concentration of IL-33 in bronchoalveolar lavage fluid (BALF) samples. Samples were obtained from patients with foreign body (FB, control, n = 15) and patients with M. pneumoniae pneumonia (MPP, n = 30). Data are presented as mean ± SD, significance was determined by Mann–Whitney U test. *, p < 0.05; **, p < 0.01, compared with FB. (D) ROC curve analysis of the diagnostic efficacy of IL-33 between MPP patients and control (AUC = 0.727).